Pluri Inc (PLUR)

$1.08 0.00 (N/A)
Market Cap 13.33M
Revenue (ttm) 1.02M
Net Income (ttm) -23.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,335.29%
Debt to Equity Ratio -1.62
Volume 23,800
Avg Vol 27,084
Day's Range N/A - N/A
Shares Out 12.35M
Stochastic %K 16%
Beta 0.68
Analysts Strong Buy
Price Target $12.00

Company Profile

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 74 710 8600
Address:
MATAM Advanced Technology Park, Building No. 5, Haifa, Israel
Bumbleclod
Bumbleclod Sep. 18 at 10:14 AM
$PLUR going below a buck and then bye-bye, scam company.....
0 · Reply
Bumbleclod
Bumbleclod Sep. 9 at 7:21 PM
$PLUR reminder for anyone considering this junk. I'm up 60% on my short and I'm going to ride it to the pink sheets...........
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 21 at 12:37 PM
$PLUR Below are all the different Cancers PLX-CAR-MAIT Cells MAY POTENTIALLY BE ABLE TO TREAT!!! These Cancer Tumor Antigens Below Are Listed in Pluri's Patent .....Posted on August 20, 2026. 🩸 CD 19 Acute Lymphoblastic Leukemia (ALL) Chronic Lymphocytic Leukemia (CLL) B-cell Non-Hodgkin Lymphomas Multiple Myeloma 🫁 Mesothelin Pancreatic Cancer Ovarian Cancer Non-Small Cell Lung Cancer (NSCLC) 🧪 GPC3 (Glypican-3) Breast Cancer (specifically HER2-positive subtypes) Gastric Cancer (Stomach cancer) Esophageal Cancer Colorectal Cancer Bladder and Ovarian Cancers 🧬 EGFR (Epidermal Growth Factor Receptor) Non-Small Cell Lung Cancer (NSCLC) Glioblastoma Colorectal Cancer Gastric and Pancreatic Cancers Lung Cancer Medullary Thyroid Carcinoma 🔒 Claudin 18.2 Gastric Cancer Gastroesophageal Junction (GEJ) Adenocarcinoma Pancreatic Ductal Adenocarcinoma Esophageal Adenocarcinoma 🛡️ MUC1 (Mucin 1) Breast Cancer Breast Cancer) Pancreatic Cancer Lung Cancer Ovarian and Prostate Cancers
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 20 at 1:52 PM
$PLUR Incredible !!! CAR-MAIT cells armored with a membrane-bound cytokine and a secreted cytokine in accordance with the present invention demonstrate potent antitumor activity with sustained functional persistence in serial rechallenge and spheroid killing assays.
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 20 at 1:47 PM
$PLUR WOW !!! These ENGINEERED PLX-MAIT CELLS CAN PERSIST FOR A LONG PERIOD OF TIME IN THE TUMOR ENVIRONMENT! SUMMARY OF THE INVENTION In one aspect, the present invention is directed to placental MAIT cells armored with a first bound cytokine and a second secreted cytokine for a cell therapy treatment for solid cancer tumors. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2026172343&_cid=P22-MT1JXZ-20595-1
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 18 at 4:43 PM
$PLUR https://www.seafoodsource.com/news/ever-after-foods-acquires-cell-cultured-seafood-producer-fishway
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 18 at 4:38 PM
$PLUR https://vegconomist.com/investments-finance/ever-after-foods-buys-belgian-startup-fishway-add-aquatic-cell-biology-cultivated-protein-platform/
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 18 at 9:21 AM
$PLUR Ever After Foods https://www.greenqueen.com.hk/ever-after-foods-funding-fishway-acquisition-cultivated-lab-grown-meat/
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 17 at 1:46 PM
$PLUR Pluri’s Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment https://pluri-biotech.com/investors-news/
0 · Reply
Bumbleclod
Bumbleclod Aug. 4 at 4:15 AM
$PLUR somebody's short position is looking superb...........
0 · Reply
Latest News on PLUR
Pluri files $200M mixed securities shelf

2026-09-11T10:05:35.000Z - 9 days ago

Pluri files $200M mixed securities shelf

Pluri prices 2.23M shares at $1.50 in registered direct offering

2026-08-27T12:20:19.000Z - 24 days ago

Pluri prices 2.23M shares at $1.50 in registered direct offering

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Aug 27, 2026, 8:00 AM EDT - 24 days ago

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Aug 17, 2026, 9:00 AM EDT - 4 weeks ago

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

Jul 28, 2026, 8:00 AM EDT - 7 weeks ago

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

Pluri announces chairman Alejandro Weinstein ownership surpasses 30%

2026-07-14T11:20:34.000Z - 2 months ago

Pluri announces chairman Alejandro Weinstein ownership surpasses 30%

Plurilock Announces Results of Annual General Meeting

Jun 16, 2026, 5:05 PM EDT - 3 months ago

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Jun 2, 2026, 7:30 AM EDT - 3 months ago

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri announces additional $2.5M investment from Alejandro Weinstein

2026-03-26T12:46:49.000Z - 5 months ago

Pluri announces additional $2.5M investment from Alejandro Weinstein

Pluri secures global IP position with CNIPA for immune cell expansion

2026-02-18T13:26:26.000Z - 7 months ago

Pluri secures global IP position with CNIPA for immune cell expansion

Pluri completes first phase of program with Resbiomed Technologies OOD

2026-01-22T14:20:47.000Z - 8 months ago

Pluri completes first phase of program with Resbiomed Technologies OOD

Pluri announces expansion of manufacturing agreement with Remedy Cell

2025-12-22T12:10:54.000Z - 9 months ago

Pluri announces expansion of manufacturing agreement with Remedy Cell

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Dec 22, 2025, 7:00 AM EST - 9 months ago

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Pluri appoints Weinstein as Chairman of the Board of Directors

2025-12-09T13:45:37.000Z - 9 months ago

Pluri appoints Weinstein as Chairman of the Board of Directors

Pluri announces launch of Cellav Health and Aesthetics

2025-11-11T13:10:38.000Z - 10 months ago

Pluri announces launch of Cellav Health and Aesthetics

Pluri enters series of international collaborations

2025-11-10T13:15:46.000Z - 10 months ago

Pluri enters series of international collaborations

Pluri subsidiary Coffeesai announces strategic collaboration for manufacturing

2025-10-08T13:10:10.000Z - 11 months ago

Pluri subsidiary Coffeesai announces strategic collaboration for manufacturing

Pluri files to sell 3.425M common shares for holders

2025-09-17T21:30:45.000Z - 1 year ago

Pluri files to sell 3.425M common shares for holders

Pluri re-initiated with a Buy at Alliance Global Partners

2025-06-02T11:05:14.000Z - 1 year ago

Pluri re-initiated with a Buy at Alliance Global Partners

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

May 27, 2025, 7:00 AM EDT - 1 year ago

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

Pluri CEO issues letter to shareholders

2025-05-15T11:19:26.000Z - 1 year ago

Pluri CEO issues letter to shareholders

Pluri completes strategic acquisition of 71% of equity of Kokomodo for $4.5M

2025-04-28T12:22:41.000Z - 1 year ago

Pluri completes strategic acquisition of 71% of equity of Kokomodo for $4.5M

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Pluri announces USPTO issued patent covering its immune cell expansion tech

2025-04-10T12:35:28.000Z - 1 year ago

Pluri announces USPTO issued patent covering its immune cell expansion tech

Pluri announces exclusive collaboration agreement with Hemafund

2025-03-05T12:23:18.000Z - 1 year ago

Pluri announces exclusive collaboration agreement with Hemafund

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Mar 5, 2025, 7:00 AM EST - 1 year ago

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

Feb 19, 2025, 9:01 AM EST - 1 year ago

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

Pluri secures additional $3.5M investment from Merchant Adventure Fund

2025-02-04T12:16:15.000Z - 1 year ago

Pluri secures additional $3.5M investment from Merchant Adventure Fund

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

Jan 23, 2025, 7:15 AM EST - 1 year ago

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

Dec 19, 2024, 8:00 AM EST - 1 year ago

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

Nov 12, 2024, 1:00 PM EST - 1 year ago

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Nov 11, 2024, 6:00 AM EST - 1 year ago

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

Jul 18, 2024, 2:30 AM EDT - 2 years ago

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

Jun 18, 2024, 6:30 AM EDT - 2 years ago

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

Jun 6, 2024, 6:45 AM EDT - 2 years ago

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

May 20, 2024, 7:00 AM EDT - 2 years ago

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

May 2, 2024, 7:00 AM EDT - 2 years ago

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Mar 28, 2024, 7:15 AM EDT - 2 years ago

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Pluri Inc. Announces 1-for-8 Reverse Share Split

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Pluri Inc. Announces 1-for-8 Reverse Share Split

Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Mar 19, 2024, 4:00 AM EDT - 2 years ago

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

Mar 14, 2024, 7:00 AM EDT - 2 years ago

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Mar 6, 2024, 7:00 AM EST - 2 years ago

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Feb 28, 2024, 7:00 AM EST - 2 years ago

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Jan 23, 2024, 2:00 AM EST - 2 years ago

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Jan 8, 2024, 7:00 AM EST - 2 years ago

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Pluri's PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Pluri's PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

Jul 13, 2023, 2:00 AM EDT - 3 years ago

Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri's PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Jul 11, 2023, 2:00 AM EDT - 3 years ago

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri's PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

Apr 27, 2023, 7:00 AM EDT - 3 years ago

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

Israel's Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

Mar 13, 2023, 8:00 AM EDT - 3 years ago

Israel's Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept

Dec 22, 2022, 7:00 AM EST - 3 years ago

Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept

Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

Dec 15, 2022, 4:05 PM EST - 3 years ago

Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

Pluri wins BioTech Breakthrough Cell Innovation of the Year Award

Nov 10, 2022, 7:00 AM EST - 3 years ago

Pluri wins BioTech Breakthrough Cell Innovation of the Year Award

Pluri to Present and Participate in Upcoming Conferences

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Pluri to Present and Participate in Upcoming Conferences

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

Sep 29, 2022, 7:00 AM EDT - 3 years ago

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment

Sep 6, 2022, 7:00 AM EDT - 4 years ago

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment

Pluri CEO Issues Shareholder Update

Jul 25, 2022, 7:00 AM EDT - 4 years ago

Pluri CEO Issues Shareholder Update

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

Jul 25, 2022, 1:00 AM EDT - 4 years ago

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Jul 13, 2022, 6:00 AM EDT - 4 years ago

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Mar 28, 2022, 3:00 AM EDT - 4 years ago

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Mar 23, 2022, 7:30 AM EDT - 4 years ago

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

Mar 8, 2022, 7:12 AM EST - 4 years ago

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

Pluristem CEO Issues Shareholder Update

Mar 2, 2022, 7:00 AM EST - 4 years ago

Pluristem CEO Issues Shareholder Update

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Feb 24, 2022, 7:00 AM EST - 4 years ago

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Jan 10, 2022, 3:00 AM EST - 4 years ago

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Bumbleclod
Bumbleclod Sep. 18 at 10:14 AM
$PLUR going below a buck and then bye-bye, scam company.....
0 · Reply
Bumbleclod
Bumbleclod Sep. 9 at 7:21 PM
$PLUR reminder for anyone considering this junk. I'm up 60% on my short and I'm going to ride it to the pink sheets...........
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 21 at 12:37 PM
$PLUR Below are all the different Cancers PLX-CAR-MAIT Cells MAY POTENTIALLY BE ABLE TO TREAT!!! These Cancer Tumor Antigens Below Are Listed in Pluri's Patent .....Posted on August 20, 2026. 🩸 CD 19 Acute Lymphoblastic Leukemia (ALL) Chronic Lymphocytic Leukemia (CLL) B-cell Non-Hodgkin Lymphomas Multiple Myeloma 🫁 Mesothelin Pancreatic Cancer Ovarian Cancer Non-Small Cell Lung Cancer (NSCLC) 🧪 GPC3 (Glypican-3) Breast Cancer (specifically HER2-positive subtypes) Gastric Cancer (Stomach cancer) Esophageal Cancer Colorectal Cancer Bladder and Ovarian Cancers 🧬 EGFR (Epidermal Growth Factor Receptor) Non-Small Cell Lung Cancer (NSCLC) Glioblastoma Colorectal Cancer Gastric and Pancreatic Cancers Lung Cancer Medullary Thyroid Carcinoma 🔒 Claudin 18.2 Gastric Cancer Gastroesophageal Junction (GEJ) Adenocarcinoma Pancreatic Ductal Adenocarcinoma Esophageal Adenocarcinoma 🛡️ MUC1 (Mucin 1) Breast Cancer Breast Cancer) Pancreatic Cancer Lung Cancer Ovarian and Prostate Cancers
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 20 at 1:52 PM
$PLUR Incredible !!! CAR-MAIT cells armored with a membrane-bound cytokine and a secreted cytokine in accordance with the present invention demonstrate potent antitumor activity with sustained functional persistence in serial rechallenge and spheroid killing assays.
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 20 at 1:47 PM
$PLUR WOW !!! These ENGINEERED PLX-MAIT CELLS CAN PERSIST FOR A LONG PERIOD OF TIME IN THE TUMOR ENVIRONMENT! SUMMARY OF THE INVENTION In one aspect, the present invention is directed to placental MAIT cells armored with a first bound cytokine and a second secreted cytokine for a cell therapy treatment for solid cancer tumors. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2026172343&_cid=P22-MT1JXZ-20595-1
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 18 at 4:43 PM
$PLUR https://www.seafoodsource.com/news/ever-after-foods-acquires-cell-cultured-seafood-producer-fishway
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 18 at 4:38 PM
$PLUR https://vegconomist.com/investments-finance/ever-after-foods-buys-belgian-startup-fishway-add-aquatic-cell-biology-cultivated-protein-platform/
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 18 at 9:21 AM
$PLUR Ever After Foods https://www.greenqueen.com.hk/ever-after-foods-funding-fishway-acquisition-cultivated-lab-grown-meat/
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Aug. 17 at 1:46 PM
$PLUR Pluri’s Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment https://pluri-biotech.com/investors-news/
0 · Reply
Bumbleclod
Bumbleclod Aug. 4 at 4:15 AM
$PLUR somebody's short position is looking superb...........
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Jul. 28 at 1:16 PM
$PLUR Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK https://pluri-biotech.com/investors-news/
0 · Reply
DJtraderNY
DJtraderNY Jul. 26 at 8:01 PM
$PLUR reverse split coming soon
2 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Jul. 14 at 11:43 PM
$PLUR It Looks Like They Have Struck A Deal With The EIB !
0 · Reply
focafoca99
focafoca99 Jul. 14 at 8:18 PM
$PLUR remains in talks with the EIB to resolve its overdue €20 million loan, pending internal approval and legal review.
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Jul. 14 at 12:05 PM
$PLUR Pluri can already produce tailored exosomes with distinct biological cargo profiles. We believe this capability could support a future generation of biologic products and attract interest from strategic investors and pharmaceutical companies. Together with reproducible cell production at scale, this creates a differentiated foundation for commercialization.
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Jul. 14 at 11:27 AM
$PLUR Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30% https://markets.businessinsider.com/news/stocks/pluri-chairman-alejandro-weinstein-s-cumulative-investment-exceeds-17-million-ownership-surpasses-30-1036322521
0 · Reply
Bumbleclod
Bumbleclod Jul. 9 at 12:29 AM
$PLUR @Jaimedav Fair warning newbees......
0 · Reply
Jaimedav
Jaimedav Jun. 30 at 5:03 PM
$PLUR .. this company has always been a scam, with fake headlines that have never materialized. It should be shut down
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Jun. 30 at 3:36 PM
$PLUR Page 14 of today's Pluri Company Presentation basically says.... Each Partnership will go to an IPO or Corporate Buyout ! Good News for Shareholders!!! Page 14: Strategic transactions and partnerships - each venture engineered with built-in exit routes, positioning every collaboration for a value-realization event.
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Jun. 30 at 1:53 PM
$PLUR Pluri Company Presentation Out Today !!! https://pluri-biotech.com/presentation/
0 · Reply
focafoca99
focafoca99 Jun. 22 at 8:19 PM
$PLUR agrees to a $1.25 million advance subscription agreement to boost working capital, with the funds received June 16.
0 · Reply
PLURI_JUGGERNAUT_
PLURI_JUGGERNAUT_ Jun. 11 at 4:39 PM
$PLUR COFFEE AND CACAO BIOTECH SOLUTION TO CLIMATE CHANGE https://www.youtube.com/watch?v=Ql2snjmmZYs
0 · Reply